{"title":"Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer","authors":"Jun Miyaguchi , Kiyoto Shiga , Katsunori Katagiri , Daisuke Saito , Kodai Tsuchida , Takahiro Kusaka , Yu Ohashi , Iori Kusaka , Yoshihiro Takai","doi":"10.1016/j.oraloncology.2025.107228","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although BNCT is a novel therapy for head and neck cancers, its efficacy in patients with oral cancer remains unclear.</div></div><div><h3>Patients and methods</h3><div>Nine patients with oral cancer underwent BNCT at Southern Tohoku BNCT Research Center. We reviewed the charts and diagnostic images of these patients and analyzed their responses and adverse events associated with the therapy.</div></div><div><h3>Results</h3><div>All patients underwent surgery and/or radiotherapy as initial treatment for head and neck cancer. No patients had distant metastases at the time of BNCT. The median observation period was 16 months. Grade 3 and 4 adverse events were observed in six patients who recovered within one month. Treatment responses were complete in seven patients and partial in two. Overall survival, disease-specific survival, and local control rates of the patients at one year were 76.2, 76.2, and 87.5 %, respectively.</div></div><div><h3>Conclusion</h3><div>Our study suggested that BNCT is a relatively safe and effective treatment for patients with recurrent and/or advanced oral cancer.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107228"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837525000570","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Although BNCT is a novel therapy for head and neck cancers, its efficacy in patients with oral cancer remains unclear.
Patients and methods
Nine patients with oral cancer underwent BNCT at Southern Tohoku BNCT Research Center. We reviewed the charts and diagnostic images of these patients and analyzed their responses and adverse events associated with the therapy.
Results
All patients underwent surgery and/or radiotherapy as initial treatment for head and neck cancer. No patients had distant metastases at the time of BNCT. The median observation period was 16 months. Grade 3 and 4 adverse events were observed in six patients who recovered within one month. Treatment responses were complete in seven patients and partial in two. Overall survival, disease-specific survival, and local control rates of the patients at one year were 76.2, 76.2, and 87.5 %, respectively.
Conclusion
Our study suggested that BNCT is a relatively safe and effective treatment for patients with recurrent and/or advanced oral cancer.
期刊介绍:
Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck.
Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.